Newsroom

Partnership
Nanyang Biologics and Precisya Global Form Strategic Alliance to Leverage AI in Validating Natural Compounds for Genetic Risk Mitigation
Nanyang Biologics (NYB) and Precisya Global Inc. (PGI) have partnered to combine AI-powered compound discovery with advanced genetic risk profiling - bringing a new dimension to precision health through nature-derived interventions.
May 3, 2025

Company
Nanyang Biologics at GITEX ASIA SINGAPORE 2025
Nanyang Biologics will be joining GITEX ASIA – Asia’s largest and most global tech, startup, and digital investment event – taking place from April 23 to 25 at Marina Bay Sands, Singapore.

Company
Nanyang Biologics - NTU Joint Laboratory
A pioneering collaboration with Nanyang Technological University Singapore with the NYB - NTU Joint Laboratory, aiming at revolutionizing drug discovery through the power of AI and natural compounds.

Partnership
Nanyang Biologics Joins NVIDIA GTC 2025: Advancing AI in Drug Discovery
Nanyang Biologics is revolutionizing drug discovery with AI at NVIDIA GTC 2025! Discover how we’re using the latest technologies to accelerate life-saving innovations.

Publications
Publication of DTIGN on IEEE Xplore
Advancing Bioactivity Prediction Through Molecular Docking and Self-Attention.

Company
Unlocking Nature’s Potential for Breakthrough Therapies with DTIGN
Nanyang Biologics' AI-driven DTIGN platform revolutionizes natural compound drug discovery with great accuracy, efficiency, and speed, unlocking nature's vast therapeutic potential for breakthrough treatments.

Partnership
Nanyang Biologics Joins Prestigious Johnson & Johnson Innovation JLABS to Accelerate AI-Driven Drug Discovery
Nanyang Biologics becomes a resident company of JLABS, joining a global network dedicated to accelerating life-enhancing health and wellness solutions.

Partnership
Nanyang Biologics Joins NVIDIA & Tribe’s Prestigious Ignition Program
Nanyang Biologics harnesses NVIDIA AI and accelerated computing to transform $7 billion drug discovery industry.
No items found.
No items found.

Company
Nanyang Biologics at GITEX ASIA SINGAPORE 2025
Nanyang Biologics will be joining GITEX ASIA – Asia’s largest and most global tech, startup, and digital investment event – taking place from April 23 to 25 at Marina Bay Sands, Singapore.

Company
Nanyang Biologics - NTU Joint Laboratory
A pioneering collaboration with Nanyang Technological University Singapore with the NYB - NTU Joint Laboratory, aiming at revolutionizing drug discovery through the power of AI and natural compounds.

Company
Unlocking Nature’s Potential for Breakthrough Therapies with DTIGN
Nanyang Biologics' AI-driven DTIGN platform revolutionizes natural compound drug discovery with great accuracy, efficiency, and speed, unlocking nature's vast therapeutic potential for breakthrough treatments.

Partnership
Nanyang Biologics and Precisya Global Form Strategic Alliance to Leverage AI in Validating Natural Compounds for Genetic Risk Mitigation
Nanyang Biologics (NYB) and Precisya Global Inc. (PGI) have partnered to combine AI-powered compound discovery with advanced genetic risk profiling - bringing a new dimension to precision health through nature-derived interventions.

Partnership
Nanyang Biologics Joins NVIDIA GTC 2025: Advancing AI in Drug Discovery
Nanyang Biologics is revolutionizing drug discovery with AI at NVIDIA GTC 2025! Discover how we’re using the latest technologies to accelerate life-saving innovations.

Partnership
Nanyang Biologics Joins Prestigious Johnson & Johnson Innovation JLABS to Accelerate AI-Driven Drug Discovery
Nanyang Biologics becomes a resident company of JLABS, joining a global network dedicated to accelerating life-enhancing health and wellness solutions.

Partnership
Nanyang Biologics Joins NVIDIA & Tribe’s Prestigious Ignition Program
Nanyang Biologics harnesses NVIDIA AI and accelerated computing to transform $7 billion drug discovery industry.
No items found.

Publications
Publication of DTIGN on IEEE Xplore
Advancing Bioactivity Prediction Through Molecular Docking and Self-Attention.